## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Vashington,	D.C. 20549	

STATEMENT	OE (	CHANGES	INI I	DENIEFICIAL	OWNEDGLID
SIAIEMENI	OF (	SHANGES	1114 1	DENEFICIAL	OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Reider Paul					2. Issuer Name and Ticker or Trading Symbol Coherus BioSciences, Inc. [ CHRS ]							Relationship of Reporting Person(s) to Issuer (Check all applicable)     Director 10% Owner					
(Last)	`	irst) ENCES, INC.	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 01/02/2024						X	Chief Commercial Officer  Other (specific below)  Chief Commercial Officer				pecify	
333 TWIN DOLPHIN DRIVE, SUITE 600				4	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) REDWO	OOD C.	A	94065								) X	_	,	•	ting Person One Reporti	ng	
					Rule 10b5-1(c) Transaction Indication												
(City)	(S	tate)	(Zip)		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date			2. Transact Date (Month/Day	Execution Date		Code (Instr.				5. Amoun Securities Beneficia Owned Fo	Form (D) or		n: Direct In r Indirect E sstr. 4) C	7. Nature of ndirect Beneficial Dwnership Instr. 4)			
						Code V	Amount	nt (A) or (D) Pr		Transacti (Instr. 3 a	action(s)			Ju. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security  1. Title of Conversion or Exercise (Instr. 3)  2. Conversion Date (Month/Day/Year)  3. Transaction Date Execution Date, if any (Month/Day/Year)  3. Deemed Execution Date, if any (Month/Day/Year)		Code	ransaction Derivative ode (Instr. Securities		e s I (A) sed str.	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)				
Stock Option (Right to Buy)	\$3.14	01/02/2024		A		160,000		(1)	01/02/2034	Common Stock	160,000	\$0	160,00	00	D		

## **Explanation of Responses:**

1. 1/48th of the total number of shares subject to the option shall vest in successive, equal monthly installments measured from January 2, 2024, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

/s/ Bryan McMichael, as

Attorney-in-Fact for Paul

01/04/2024

Reider

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.